Cell Death News and Research

RSS

3SBio's first-quarter 2010 total net revenues up 40.5%

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2010.

17 May 2010

Measuring gene expression in healthy women may predict future breast cancer risk, say scientists

Researchers at Georgetown Lombard Comprehensive Cancer Center have been able to show, in mice, how just a little adjustment in the expression of two common genes can promote the kind of cellular changes that led to breast cancer. They say these tweaks likely mimic natural variation women have in expression of the two genes.

14 May 2010

Researchers determine how cells regulate chromosome/microtubule interface

Whitehead Institute researchers have determined a key part of how cells regulate the chromosome/microtubule interface, which is central to proper chromosomal distribution during cell division.

14 May 2010

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

13 May 2010

New combination therapy may help treat anti-estrogen resistant ER+ breast cancer

A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor positive breast cancers.

11 May 2010

Three Hamilton scientists receive cancer research grants from Canadian Cancer Society

Three Hamilton scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.

5 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

Researchers convert established human iPS cells, ES cells to base state of greater pluripotency

Whitehead Institute researchers have converted established human induced pluripotent stem cells and human embryonic stem cells to a base state of greater pluripotency.

4 May 2010

Scientist to receive 2010 March of Dimes Prize in Developmental Biology

The scientist who reprogrammed adult cells into embryonic-like stem cells has been chosen to receive the 2010 March of Dimes Prize in Developmental Biology.

3 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model.

30 Apr 2010

Study promises a new treatment for cancer

Cancer cells producing toxins that destroy tumours - could this be a future treatment for cancer? Researchers at Lund University have achieved good results in tests on both cells and animals.

30 Apr 2010

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions. There are currently no treatment options for people with this debilitating disease. The research is published in the April 27 issue of Proceedings of the National Academy of Sciences.

28 Apr 2010

Potential new treatment for osteonecrosis

28 Apr 2010

Mechanisms pathogenic viruses exploit to evade immune systems of hosts

Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers led by LMU virologist Professor J-rgen Haas has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose, and their latest results could point the way to new antiviral therapies. The mechanism is based on the production of short RNA molecules, called microRNAs, by the virus.

24 Apr 2010

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.

23 Apr 2010

Larger sized intravenous anesthetic diazepam incubated in isolation with Aβ peptide does not promote aggregation

Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions of people worldwide and has become a major global concern. Uncontrolled oligomerization (aggregation) of Aβ peptide is the hallmark of AD and it is believed to be causally related to AD pathomechanism.

22 Apr 2010

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported results from two studies on the development of ribonuclease-based immunotoxins at the American Association for Cancer Research conference.

22 Apr 2010

Cell Death News and Research

3SBio's first-quarter 2010 total net revenues up 40.5%

Measuring gene expression in healthy women may predict future breast cancer risk, say scientists

Researchers determine how cells regulate chromosome/microtubule interface

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

New combination therapy may help treat anti-estrogen resistant ER+ breast cancer

Three Hamilton scientists receive cancer research grants from Canadian Cancer Society

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Researchers convert established human iPS cells, ES cells to base state of greater pluripotency

Scientist to receive 2010 March of Dimes Prize in Developmental Biology

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Study promises a new treatment for cancer

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Potential new treatment for osteonecrosis

Mechanisms pathogenic viruses exploit to evade immune systems of hosts

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Larger sized intravenous anesthetic diazepam incubated in isolation with Aβ peptide does not promote aggregation

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News